Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2251-2260

  Khanbolooki, Sanaz ^a   Nawrocki, Steffan T ^a   Arumugam, Thiruvengadam ^a   Andtbacka, Robert ^a   Pino, Maria S ^a,b   Kurzrock, Razelle ^a   Logsdon, Craig D ^a   Abbruzzese, James L ^a   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BORTEZOMIB; DEATH RECEPTOR; DNA FRAGMENT; I KAPPA B ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; PROTEIN BCL XL; SMALL INTERFERING RNA; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; BORONIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PYRAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BORONIC ACIDS; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; PYRAZINES; PYRIDINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749578608     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0075     Document Type: Article

References (41)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671-7.
3. Mulcahy MF, Wahl AO, Small W, Jr. The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. J Natl Compr Canc Netw 2005;3:637-42.
4. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 2004;6:199-206.
5. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.
6. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/ TRAIL. Curr Opin Pharmacol 2004;4:333-9.
7. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001;163:71-81.
8. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001;23:72-9.
9. Liao Q, Friess H, Kleeff J, Buchler MW. Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res 2001;21:3153-9.
10. Bai J, Sui J, Demirjian A, Vollmer CM, Jr., Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005;65:2344-52.
11. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066-75.
12. Orlowski RZ, Baldwin AS, Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
13. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
14. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-62.
15. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κ B ReIA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5: 119-27.
16. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004; 6:203-8.
17. Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol 2001;3:409-16.
18. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274: 784-7.
19. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
20. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
21. Anderson KC. Clinical update: novel targets in multiple myeloma. Semin Oncol 2004;31:27-32; discussion 3.
22. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Protea-some inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
23. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.
24. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-53.
25. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139: 271-9.
26. Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 2006;55:76-84.
27. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005;4:443-9.
28. Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005;77-82.
29. Papageorgiou A, Lashinger L, Millikan R, et al. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res 2004;64:8973-9.
30. Yin D, Zhou H, Kumagai T, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-54.
31. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18:1699-704.
32. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003;9:4537-45.
33. Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22:4953-63.
34. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10.
35. Lashinger L, Zhu K, Williams S, Shrader M, Dinney CP, McConkey D. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005;65:4902-8.
36. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3: 59-70.
37. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
38. Roychowdhury S, Baiocchi RA, Vourganti S, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst 2004;96:1447-57.
39. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11:28-40.
40. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
41. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002;1:82-9.